Amgen Q1 2026: Record Revenue, New Drugs Drive Growth

Amgens Q1 2026 earnings soared, with revenue hitting $8.62 billion, up 5.8% year-over-year and beating estimates by 1.4%. Adjusted earnings per share came in at $5.15, 8% above expectations, while EBITDA topped $5.13 billion. Newer drugs like Repatha and Evenity drove growth, now making up nearly 70% of total sales. Despite a slight stock dip, Amgens market cap remains strong at $186.9 billion. The company is investing in AI for drug discovery and manufacturing, and investors should watch for trial data, Repatha and Evenity expansion, and AI rollout progress. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:advertise@thednn.ai This is an automated, high-level news summary based on public reporting.Report issues to feedback@thednn.ai. View sources & latest updates:https://sources.thednn.ai/1e496275f4279750